Application value of magnetic resonance spectroscopy imaging in the diagnosis of prostate cancer.
Diagnosis
Magnetic resonance spectroscopy
Pathology
Prostate cancer
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 Sep 2024
27 Sep 2024
Historique:
received:
30
05
2024
accepted:
19
09
2024
medline:
28
9
2024
pubmed:
28
9
2024
entrez:
27
9
2024
Statut:
epublish
Résumé
Magnetic resonance spectroscopy (MRSI) can distinguish between benign and malignant prostate diseases. This study investigated the potential of MRSI for diagnosing prostate cancer and guiding prostate biopsy. We retrospectively reviewed 234 patients with suspected prostate cancer who underwent MRSI with targeted prostate biopsy. Patients were divided into two groups according to their puncture pathology: prostate cancer (n = 103, 44.02%) and benign prostatic disease (n = 131, 55.98%). The t-test, Mann-Whitney U test, or chi-square test was used to compare the groups. The diagnostic abilities of MRSI, prostate-specific antigen level, digital rectal examination, and magnetic resonance imaging without contrast for prostate cancer were compared using the area under the receiver operating characteristic curve (AUC-ROC); the ARC-ROC values were 0.831, 0.768, 0.692, and 0.656, respectively. The AUC-ROC value for diagnosing prostate cancer using the CC/c ratio was 0.853. CC/c ratio > 0.97 was identified as the optimal threshold for diagnosing prostate cancer (sensitivity, 86.5%; specificity, 78.6%; Youden index, 0.651). Spearman correlation analysis revealed a correlation between the CC/c ratio and Gleason score (r = 0.737, p < 0.001). Using the CC/c ratio of MRSI as an adjunct to targeted prostate biopsy can improve the detection rate of positive biopsies and evaluate prostate cancer invasiveness.
Identifiants
pubmed: 39333720
doi: 10.1038/s41598-024-73605-3
pii: 10.1038/s41598-024-73605-3
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
22278Informations de copyright
© 2024. The Author(s).
Références
National Cancer Center & Prostate Cancer Expert Committee of National Cancer Quality Control Center. Quality control index for standardized diagnosis and treatment of prostate cancer in China (2022 edition). Zhonghua Zhong Liu Za Zhi44, 1011–1016 (2022).
Wegener, D. et al. Primary treatment of prostate cancer using 1.5 T MR-linear accelerator. Radiologe61, 839–845 (2021).
doi: 10.1007/s00117-021-00882-8
pubmed: 34297139
Huebner, N. A. et al. Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)-do we still need contrast media? Eur. Radiol.31, 3754–3764 (2021).
doi: 10.1007/s00330-020-07494-1
pubmed: 33263793
Sui, Y., Li, J., Zou, Z., Shi, Y. & Hao, C. Comparison of diagnostic value of multi-slice spiral CT and MRI for different pathological stages of prostate cancer. Oncol. Lett.17, 5505–5510 (2019).
pubmed: 31186770
Stabile, A. et al. Multiparametric MRI for prostate cancer diagnosis: current status and future directions. Nat. Rev. Urol.17, 41–61 (2020).
doi: 10.1038/s41585-019-0212-4
pubmed: 31316185
Andersen, M. K. et al. Integrative metabolic and transcriptomic profiling of prostate cancer tissue containing reactive stroma. Sci. Rep.8, 14269 (2018).
doi: 10.1038/s41598-018-32549-1
pubmed: 30250137
Kumar, V., Bora, G. S., Kumar, R. & Jagannathan, N. R. Multiparametric (mp) MRI of prostate cancer. Prog Nucl. Magn. Reson. Spectrosc.105, 23–40 (2018).
doi: 10.1016/j.pnmrs.2018.01.001
pubmed: 29548365
Jung, J. A. et al. Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system. Radiology233, 701–708 (2004).
doi: 10.1148/radiol.2333030672
pubmed: 15564406
Caivano, R. et al. Prostate cancer in magnetic resonance imaging: diagnostic utilities of spectroscopic sequences. J. Med. Imaging Radiat. Oncol.56, 606–616 (2012).
doi: 10.1111/j.1754-9485.2012.02449.x
pubmed: 23210579
Kumar, V., Jagannathan, N. R., Thulkar, S. & Kumar, R. Prebiopsy magnetic resonance spectroscopy and imaging in the diagnosis of prostate cancer. Int. J. Urol.19, 602–613 (2012).
doi: 10.1111/j.1442-2042.2012.02995.x
pubmed: 22435389
Casciani, E. et al. Contribution of the MR spectroscopic imaging in the diagnosis of prostate cancer in the peripheral zone. Abdom. Imaging32, 796–802 (2007).
doi: 10.1007/s00261-007-9181-9
pubmed: 17294342
Zakian, K. L. et al. Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy. Radiology234, 804–814 (2005).
doi: 10.1148/radiol.2343040363
pubmed: 15734935
Zabihzadeh, M. et al. Accuracy of magnetic resonance spectroscopy techniques in prostate cancer and prostatitis. Arch. Iran. Med.23, 104–112 (2020).
pubmed: 32061073
Lahoti, A. M. et al. Role of magnetic resonance imaging, magnetic resonance spectroscopy and transrectal ultrasound in evaluation of prostatic pathologies with focus on prostate cancer. Pol. J. Radiol.82, 827–836 (2017).
doi: 10.12659/PJR.903958
pubmed: 29657651
Williams, I. S. et al. Modern paradigms for prostate cancer detection and management. Med. J. Aust217, 424–433 (2022).
doi: 10.5694/mja2.51722
pubmed: 36183329
Ploussard, G. et al. The contemporary concept of significant versus insignificant prostate cancer. Eur. Urol.60, 291–303 (2011).
doi: 10.1016/j.eururo.2011.05.006
pubmed: 21601982
de Rooij, M. et al. ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists’ training. Eur. Radiol.30, 5404–5416 (2020).
doi: 10.1007/s00330-020-06929-z
pubmed: 32424596
Litjens, G. J., Barentsz, J. O., Karssemeijer, N. & Huisman, H. J. Clinical evaluation of a computer-aided diagnosis system for determining cancer aggressiveness in prostate MRI. Eur. Radiol.25, 3187–3199 (2015).
doi: 10.1007/s00330-015-3743-y
pubmed: 26060063
Lopci, E. et al. 68ga-PSMA positron emission tomography/computerized tomography for primary diagnosis of prostate cancer in men with contraindications to or negative multiparametric magnetic resonance imaging: a prospective observational study. J. Urol.200, 95–103 (2018).
doi: 10.1016/j.juro.2018.01.079
pubmed: 29409824
Verma, S., Rajesh, A. & Suppl A clinically relevant approach to imaging prostate cancer: self-assessment module. AJR Am. J. Roentgenol. 196 S11–S14 (2011).
Kitzing, Y. X. et al. Benign conditions that mimic prostate carcinoma: MR imaging features with histopathologic correlation. Radiographics36, 162–175 (2016).
doi: 10.1148/rg.2016150030
pubmed: 26587887
Scheenen, T. W. et al. Discriminating cancer from noncancer tissue in the prostate by 3-dimensional proton magnetic resonance spectroscopic imaging: a prospective multicenter validation study. Invest. Radiol.46, 25–33 (2011).
doi: 10.1097/RLI.0b013e3181f54081
pubmed: 21188832
Thompson, J. et al. The role of magnetic resonance imaging in the diagnosis and management of prostate cancer. BJU Int.112 (2), 6–20 (2013).
doi: 10.1111/bju.12381
pubmed: 24127671
Pinto, F. et al. Imaging in prostate cancer diagnosis: present role and future perspectives. Urol. Int.86, 373–382 (2011).
doi: 10.1159/000324515
pubmed: 21372554
Nayyar, R. et al. Magnetic resonance spectroscopic imaging: current status in the management of prostate cancer. BJU Int.103, 1614–1620 (2009).
doi: 10.1111/j.1464-410X.2009.08446.x
pubmed: 19338548
Kobus, T. et al. In vivo assessment of prostate cancer aggressiveness using magnetic resonance spectroscopic imaging at 3 T with an endorectal coil. Eur. Urol.60, 1074–1080 (2011).
doi: 10.1016/j.eururo.2011.03.002
pubmed: 21419565
Nagarajan, R. et al. MR spectroscopic imaging and diffusion-weighted imaging of prostate cancer with Gleason scores. J. Magn. Reson. Imaging36, 697–703 (2012).
doi: 10.1002/jmri.23676
pubmed: 22581787
Vandergrift, L. A. et al. Metabolomic prediction of human prostate cancer aggressiveness: magnetic resonance spectroscopy of histologically benign tissue. Sci. Rep.8, 4997 (2018).
doi: 10.1038/s41598-018-23177-w
pubmed: 29581441
Schmidt, D. R. et al. Metabolomics in cancer research and emerging applications in clinical oncology. CA Cancer J. Clin.71, 333–358 (2021).
doi: 10.3322/caac.21670
pubmed: 33982817
Weinreb, J. C. et al. PI-RADS prostate imaging-reporting and data system: 2015, Version 2. Eur. Urol.69 (1), 16–40. https://doi.org/10.1016/j.eururo.2015.08.052 (2016).
doi: 10.1016/j.eururo.2015.08.052
pubmed: 26427566
Epstein, J. I. et al. A contemporary prostate cancer grading system: a validated alternative to the gleason score. Eur. Urol.69 (3), 428–435. https://doi.org/10.1016/j.eururo.2015.06.046 (2016).
doi: 10.1016/j.eururo.2015.06.046
pubmed: 26166626